Multiple Myeloma
Featured Articles
(BMS) June 24, 2017 - Combination therapy demonstrated a sustained reduction in risk of progression/death of 29% and relative improvement of 50% in progression-free survival rate of ELd (21%) compared to Ld alone (14%); the extended follow-up data is the longest of an Immuno-Oncology agent in relapsed/refractory multiple myeloma; the...
Read Article
(4-traders) June 23, 2017 - Early studies of weekly and twice-weekly ixazomib plus lenalidomide and dexamethasone demonstrate deep responses after induction, with deepening responses seen after single-agent ixazomib maintenance; Data to be presented during two oral sessions at the 2017 European Hematology Association (EHA) Annual Meeting.
Read Article
Latest Articles
June 22, 2017
June 21, 2017
June 19, 2017
June 19, 2017
June 15, 2017
June 14, 2017
June 12, 2017
June 07, 2017
View More
News Commentary
Editor Image
02 Apr, 2017 | by Winston Wong, PharmD
Ok. So maybe the there was a bit of overexcitement from NantKwest's product. ...
View Comment
View More
OBR Green
There are no Multiple Myeloma OBR Green articles.
OBR Blog
This year's ASH Annual Meeting will be chock-full of interesting, informative, and clinically useful presentations,... Read more
November 22, 2016